Millennium Management
RARE icon

Millennium Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Millennium Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,500
Closed -$564K – 6390
2025
Q2 		$564K Buy
+15,500
New +$559K ﹤0.01% 4824

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Millennium Management's RARE Position: Q1 2026 in Review

Millennium Management increased its Ultragenyx Pharmaceutical (RARE) stake by 101% in Q1 2026, buying an estimated $20.1M and bringing the position to 1,772,184 shares worth $37.1M. The position accounts for 0.02% of the portfolio, ranked #1060.

Millennium Management first reported a position in RARE in Q1 2014 and has held it in 41 quarters since. The position peaked at $76.1M in Q2 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Millennium Management held 1,772,184 shares of Ultragenyx Pharmaceutical worth $37.1M as of Q1 2026.
  • Millennium Management bought 891,540 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $20.1M.
  • Ultragenyx Pharmaceutical made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1060 holding.
  • Millennium Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 41 quarters since.
  • Millennium Management's Ultragenyx Pharmaceutical position peaked at $76.1M in Q2 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.